best securities to invest in

The Mexican peso is headed for its largest monthly gain in nearly five years as President Donald Trump and his partisans suffer the first major legislative setback of his presidency.

This looming milestone represents drastic and, many believed, improbable, turnaround for the peso, the most heavily traded currency in Latin America: Two months ago, just as Trump was preparing to take the oath of office, the currency plunged to an all-time low. It has risen nearly 10% against the dollar since then, and since the beginning of March, the greenback has slid nearly 7% against the peso.

best securities to invest in: China Automotive Systems, Inc.(CAAS)

Advisors’ Opinion:

  • [By Monica Gerson]

    China Automotive Systems, Inc. (NASDAQ: CAAS) is projected to post its quarterly earnings at $0.20 per share on revenue of $108.22 million.

    Affimed NV (NASDAQ: AFMD) is projected to post a quarterly loss at $0.18 per share on revenue of $1.71 million.

best securities to invest in: Cyclacel Pharmaceuticals Inc.(CYCC)

Advisors’ Opinion:

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.

best securities to invest in: WEX Inc.(WEX)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Carl Icahn has big plans for the US auto-parts sector — and big retailers like AutoZone (NYSE: AZO), O’Reilly Automotive (NASDAQ: ORLY) and Advance Auto Parts (NYSE: AAP) aren’t going to like them: Link

    ECONOMIC DATA
    USA Unit Labor Costs (QoQ) for Q1 2.20% vs 2.50% consensus estimate. Nonfarm Productivity (QoQ) for Q1 0.00% vs -0.20% consensus estimate.
    US Services Purchasing Managers' Index for May is schedule for release at 9:45 a.m. ET.
    Data on factory orders for April will be released at 10:00 a.m. ET.
    The ISM non-manufacturing index for May is schedule for release at 10:00 a.m. ET.
    The labor market conditions index for May will be released at 10:00 a.m. ET.
    The Treasury is set to auction 3-and 6-month bills at 11:30 a.m. ET.
    The TD Ameritrade Investor Movement Index for May is schedule for release at 12:30 p.m. ET.
    ANALYST RATINGS
    HSBC upgraded Chevron (NYSE: CVX) from Hold to Buy
    Susquehanna upgraded Skechers (NYSE: SKX) from Neutral to Positive
    Deutsche Bank upgraded WEX (NYSE: WEX) from Hold to Buy
    Pacific Crest downgraded Apple from Overweight to Sector Weight
    RBC downgraded Perrigo (NYSE: PRGO) from Sector Perform to Underperform
    Wedbush downgraded Endocyte (NASDAQ: ECYT) from Outperform to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email minutes@benzinga.com.

best securities to invest in: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Both Evenity and Tymlos are anabolic treatments, which means they encourage bone growth, rather than merely preventing bones from becoming more brittle, as prior generation osteoporosis drugs have done. While Eli Lilly (NYSE:LLY) was the first to market a drug in this class when Forteo gained marketing approval in 2002, it has faced no competitors despite achieving $1.5 billion in global sales last year, including $770 million in the United States. All of its patents expire by August 2019.

  • [By Keith Speights]

    With this rapidly growing market, there are plenty of opportunities for investors. Zoetis (NYSE:ZTS), Merck (NYSE:MRK), and Eli Lilly (NYSE:LLY) stand out as the top animal-health companies to buy in 2017. Here’s why.

  • [By WWW.THESTREET.COM]

    Cramer recalled recently investing in Eli Lilly (LLY) on hopes the company’s Alzheimer’s research would be worth billions. As time has worn on, Lilly’s obstacles to success seem to be mounting. Not knowing if or when Lilly might see success, Cramer said he sold the stock and moved on.

  • [By WWW.THESTREET.COM]

    Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
    Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today!   Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.

  • [By Ben Levisohn]

    Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.

  • [By Johanna Bennett]

    Eli Lilly & Co. (LLY) and Biogen (BIIB) are far from the only two drug makers racing to deliver a new treatment for Alzheimers disease. But they are pretty much leading the pack.

    The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industrys version of the holy grail.

    And according to Barclays analysts Geoff Meacham and Paul Choi, the next few weeks could prove to be one of the most fertile periods in Alzheimers disease research since 2008.

    We think the most likely outcome for Lilly’s Phase 3 EXPEDITION 3 (E3) solanezumab trial is the primary cognition (ADAS-Cog14) endpoint is met (just achieving statistical significance with a p-value <0.05) and mixed results on the secondary endpoints including function (ADL), which we believe should be good enough to support a regulatory submission. While aducanumab has a marginally different mechanism of action, we nevertheless expect BIIB shares to trade in sympathy to Lilly.

    Implications for Biogen and Merck: The E3 results are likely to result in volatility for Biogen (up 20-30%, down 10-15%) as Alzheimer’s drives both long-term growth and M&A value even though aducanumab works differently from solanezumab.

    Aducanumab dose titration data is expected at the CTAD meeting (San Diego, Dec. 9). Merck’s Phase 2/3 EPOCH verubecestat (BACE) trial is scheduled to finish in June 2017 but unlike E3, PET scans/CSF tests for A were not an inclusion criteria. We think Merck shares could move 3% to 5% in either direction in sympathy to E3.

    At $76.58, Lillys share price has fallen more than 9% over the past year, while Biogen has climbed more than 9% over the same span.

best securities to invest in: Superior Drilling Products, Inc.(SDPI)

Advisors’ Opinion:

  • [By Money Morning News Team]

    Superior Drilling Products Inc.(NYSE: SDPI) is based in Utah and manufactures equipment used in drilling for the natural gas and oil mining sectors.

Leave a Reply

Your email address will not be published. Required fields are marked *